Myeloid Blood Cancer Treatment Market Segmentation:
Distribution Channel Segment Analysis
Based on distribution channel, the hospital pharmacies is expected to achieve a market share of 61% in 2037. As per the report placed by the American Society of Hematology, more than 70% of the therapies for Acute Myeloid Leukemia or Chronic Myeloid Leukemia require hospital admission for better infrastructure availability. This raises the access of the patient and avail the myeloid blood cancer treatment from the distribution channel of hospital pharmacies. The rise of medical coverage ensured higher accessibility for the patients, and dependence on hospital pharmacies increased. According to the report of EMA, more than 78% of the targeted therapies are provided through the hospital pharmacies.
Disease Type Segment Analysis
Based on type segment, the acute myeloid leukemia is dominant with an anticipated market share growth of 52.7% in 2037. According to the approval led by the FDA, more than 5 new FLT3/IDH inhibitors are introduced in the market in 2024. This resulted in an increase in survival scope of more than 42% according to the study of the National Cancer Institute. Government investment to elevate the myeloid blood cancer treatment, more than 80% of reimbursement assurance is ensured specifically for venetoclax combinations.
Our in-depth analysis of the global market includes the following segments:
|
Disease Type |
|
|
Therapy Class |
|
|
Distribution Channel |
|
